Histological type is not an independent prognostic factor for the risk pattern of breast cancer recurrences

Breast Cancer Research and Treatment

Volumn 135, Issue 1, 2012, Pages 271-280

  Kwast, Annemiek B G ^a,b   Groothuis Oudshoorn, Karin C G M ^c   Grandjean, Ilse ^a   Ho, Vincent K Y ^a   Voogd, Adri C ^d,e   Menke Pluymers, Marian B E ^f   Van Der Sangen, Maurice J C ^g   Tjan Heijnen, Vivianne C G ^d   Kiemeney, Lambertus A ^a,b   Siesling, Sabine ^a,c  

^a Department of Cancer Registry and Research   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF TWENTE   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e The Netherlands   (Netherlands)

^f ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^g CATHARINA HOSPITAL   (Netherlands)

Author keywords

Breast cancer; Disease free survival; Ductal; Hormone receptor status; Lobular; Recurrence pattern

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST SURGERY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PATIENT ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; RISK FACTOR; TUMOR DIFFERENTIATION; VISCERAL METASTASIS;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NETHERLANDS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 84865113051     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2160-z     Document Type: Article

References (42)

1. Arpino G, Bardou VJ, Clark GM et al (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6:R149-R156
2. Martinez V, Azzopardi JG (1979) Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 3:467-488 (Pubitemid 10201560)
3. Li CI, Uribe DJ, Daling JR (2005) Clinical characteristics of different histologic types of breast cancer. Br J Cancer 93:1046-1052 (Pubitemid 41548400)
4. Bharat A, Gao F, Margenthaler JA (2009) Tumor characteristics and patient outcomes are similar between invasive lobular and mixed invasive ductal/lobular breast cancers but differ from pure invasive ductal breast cancers. Am J Surg 198:516-519
5. Rakha EA, El-Sayed ME, Powe DG et al (2008) Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 44:73-83 (Pubitemid 350256943)
6. Wasif N, Maggard MA, Ko CY et al (2010) Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol 17:1862-1869
7. Sastre-Garau X, Jouve M, Asselain B et al (1996) Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77:113-120 (Pubitemid 26002745)
8. Pestalozzi BC, Zahrieh D, Mallon E et al (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 26:3006-3014
9. du Toit RS, Locker AP, Ellis IO et al (1991) An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol 17:251-257
10. Harris M, Howell A, Chrissohou M et al (1984) A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer 50:23-30 (Pubitemid 14092642)
11. Korhonen T, Huhtala H, Holli K (2004) A comparison of the biological and clinical features of invasive lobular and ductal carcinomas of the breast. Breast Cancer Res Treat 85:23-29 (Pubitemid 38437980)
12. Blanco G, Holli K, Heikkinen M et al (1990) Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer 62:142-146 (Pubitemid 20226464)
13. Clark GM, Sledge GW Jr, Osborne CK et al (1987) Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5:55-61 (Pubitemid 17007856)
14. Wei S, Li Y, Siegal GP et al (2011) Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs. Ann Diagn Pathol 15:79-83
15. Fritz A, Percy C, Jack A, Shanmugarathnam K, Sobin L, Parkin DM (2010) International classification of diseases for oncology, 3rd edn. WHO, Geneva
16. Sobin L, Wittekind C (2008) TNM atlas, 6th edn. UICC, New York
17. Rubin DB (1987) Multiple imputation for nonresponse in surveys. Wiley, New York
18. van Buuren S, Groothuis-Oudshoorn CGM (2011) mice: Multivariate imputation by chained equations in R. J Stat Softw 45:1-67
19. Silverstein MJ, Lewinsky BS, Waisman JR et al (1994) Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 73:1673-1677 (Pubitemid 24085268)
20. Jayasinghe UW, Bilous AM, Boyages J (2007) Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma? Breast J 13:479-485 (Pubitemid 47329335)
21. Cristofanilli M, Gonzalez-Angulo A, Sneige N et al (2005) Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23:41-48 (Pubitemid 41702621)
22. Molland JG, Donnellan M, Janu NC et al (2004) Infiltrating lobular carcinoma-a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast 13:389-396 (Pubitemid 39549788)
23. Toikkanen S, Pylkkanen L, Joensuu H (1997) Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 76:1234-1240 (Pubitemid 27448024)
24. Helvie MA, Paramagul C, Oberman HA et al (1993) Invasive lobular carcinoma. Imaging features and clinical detection. Investig Radiol 28:202-207 (Pubitemid 23163264)
25. Cornford EJ, Wilson AR, Athanassiou E et al (1995) Mammographic features of invasive lobular and invasive ductal carcinoma of the breast: a comparative analysis. Br J Radiol 68:450-453
26. Jatoi I, Tsimelzon A, Weiss H et al (2005) Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat 89:173-178 (Pubitemid 40249051)
27. Yeatman TJ, Cantor AB, Smith TJ et al (1995) Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg 222:549-559
28. Singletary SE, Patel-Parekh L, Bland KI (2005) Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base. Ann Surg 242:281-289 (Pubitemid 41033446)
29. Chagpar AB, Martin RC, Hagendoorn LJ et al (2004) Lumpectomy margins are affected by tumor size and histologic subtype but not by biopsy technique. Am J Surg 188:399-402 (Pubitemid 39330544)
30. Sakr RA, Poulet B, Kaufman GJ et al (2011) Clear margins for invasive lobular carcinoma: a surgical challenge. Eur J Surg Oncol 37:350-356
31. Fargeot P, Bonneterre J, Roche H et al (2004) Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol 22:4622-4630 (Pubitemid 41185076)
32. Muss HB, Tell GS, Case LD et al (1991) Perceptions of follow-up care in women with breast cancer. Am J Clin Oncol 14:55-59
33. Harake MD, Maxwell AJ, Sukumar SA (2001) Primary and metastatic lobular carcinoma of the breast. Clin Radiol 56:621-630 (Pubitemid 35023780)
34. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746 (Pubitemid 26329660)
35. Demicheli R, Biganzoli E, Boracchi P et al (2008) Recurrence dynamics does not depend on the recurrence site. Breast Cancer Res 10:R83
36. Hilsenbeck SG, Ravdin PM, de Moor CA et al (1998) Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52:227-237 (Pubitemid 29056098)
37. Demicheli R, Biganzoli E, Ardoino I et al (2010) Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrence. Cancer Sci 101:826-830
38. Jatoi I, Anderson WF, Jeong JH et al (2011) Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol 29:2301-2304
39. Demicheli R, Ardoino I, Boracchi P et al (2010) Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast. BMC Cancer 10:656
40. Nguyen PL, Taghian AG, Katz MS et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373-2378
41. Voduc KD, Cheang MC, Tyldesley S et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684-1691
42. van Buuren S, Brand JPL, Groothuis-Oudshoorn CGM et al (2006) Fully conditional specification in multivariate imputation. J Stat Comput Simul 76:1049-1064 (Pubitemid 44843816)